This study is testing a new medicine called **cadisegliatin** to help people with Type 1 Diabetes who already use insulin. It's a **Phase 3 trial**, meaning the medicine has been tested before, but researchers want to see how well it works and if it's safe for more people. The trial lasts **26 weeks** (about 6 months). Participants will be using this medicine along with insulin to see if it reduces the number of severe low blood sugar episodes, called hypoglycemia. To join, you must be over 18, have had Type 1 Diabetes for at least 5 years, and must have experienced a severe low blood sugar event recently. You also need to be using a particular insulin delivery method and a continuous glucose monitor (CGM) for the last 3 months. You cannot join if you have other types of diabetes, certain health conditions, or have used certain medications recently. **Key Points:** - **Duration:** 26 weeks of continuous therapy. - **Requirements:** Must have had a recent severe low blood sugar event and be using specific diabetes management tools. - **Restrictions:** No other types of diabetes or recent use of certain medications.